Novozymes A/S

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novonesis A/S engages in the era of biosolutions. It innovate and develop transformative biosolutions that improve the way the world produces, consumes, and lives. The company was founded on January 29, 2024 is headquartered in Lyngby, Denmark.

Mativ Inc

Investors looking for stocks in the Chemical - Specialty sector might want to consider either Mativ Holdings (MATV) or Novozymes A/S (NVZMY). But which of these two stocks offers value investors a better bang for their buck right now?

MATV vs. NVZMY: Which Stock Should Value Investors Buy Now?

Investors interested in Chemical - Specialty stocks are likely familiar with Mativ Holdings (MATV) and Novozymes A/S (NVZMY). But which of these two stocks offers value investors a better bang for their buck right now?

MATV or NVZMY: Which Is the Better Value Stock Right Now?

Here is how Novozymes A/S (NVZMY) and Paladin Energy (PALAF) have performed compared to their sector so far this year.

Are Basic Materials Stocks Lagging Novozymes (NVZMY) This Year?

Investors interested in stocks from the Chemical - Specialty sector have probably already heard of Mativ Holdings (MATV) and Novozymes A/S (NVZMY). But which of these two stocks offers value investors a better bang for their buck right now?

MATV vs. NVZMY: Which Stock Is the Better Value Option?

Is Novozymes (NVZMY) Stock Outpacing Its Basic Materials Peers This Year?

An extraordinary shareholders' meeting of Novozymes A/S will be held on  Monday March 4, 2024 at 4:00 pm CET at Boege Alle 10-12, 2970 Hoersholm, Denmark.

Invitation to an extraordinary shareholders' meeting of Novozymes A/S

This annual report has been released subsequent to the approval of the combination of Novozymes and Chr. Hansen on January 29, 2024.

The Novozymes Report 2023

Settlement of the combination of Novozymes and Chr. Hansen Holding successfully completed February 2, 2024 Company announcement No.

Settlement of the combination of Novozymes and Chr. Hansen Holding successfully completed

Novozymes A/S (NVZMF) Q4 2023 Earnings Call Transcript

Legacy Novozymes is delivering solid growth and earnings in a year characterized by changing market demands, with 6% organic sales growth in Q4 and 5% organic sales growth in 2023. This marks the last financial reporting from legacy Novozymes, and the new company, Novonesis, is already a reality.

Legacy Novozymes delivers solid last full-year results

Today, the proposed combination of the legacy companies Novozymes and Chr. Hansen is successfully completed, establishing the company Novonesis. Novonesis is a world-leading biosolutions partner for better business, healthier lives, and a healthier planet. The combined company brings together 10,000 people worldwide and an expertise that spans more than 30 different industries. Novonesis is already assisting companies around the world in meeting both business needs and the needs of the planet. COPENHAGEN, Denmark – January 29, 2024. On December 12, 2022, Novozymes and Chr. Hansen entered into an agreement to create a leading global biosolutions partner through a statutory merger of the two companies. All regulatory approvals and registrations are now in place and the proposed combination is successfully completed following the final registration with the Danish Business Authority today. Ester Baiget, President and CEO of Novonesis, says:

The combination of Novozymes and Chr. Hansen is now successfully completed, creating Novonesis – a leading global biosolutions partner

January 29, 2024 – Company announcement no. 2 Please see attachment.

Completion of the combination between Novozymes and Chr. Hansen

January 26, 2024 – Company announcement no. 1 Please see attachment.

All necessary regulatory approvals have been obtained for the combination of Novozymes and Chr. Hansen

Axalta Coating Systems

Investors with an interest in Chemical - Specialty stocks have likely encountered both Axalta Coating Systems (AXTA) and Novozymes A/S (NVZMY). But which of these two stocks presents investors with the better value opportunity right now?

AXTA or NVZMY: Which Is the Better Value Stock Right Now?

December 20, 2023 Please see attachment. Contact information Investor Relations Disa Tuominen+45 6038 5826 dkditu@chr-hansen.com Press Relations Sanne Seyer-Hansen+45 6038 6207 dksash@chr-hansen.com Attachment 2023_South Korean merger approval granted

Update on the merger approval process for the combination of Novozymes and Chr. Hansen: South Korean merger approval granted

Please read the full announcement in PDF Attachment 2023_61_Updated_financial_calendar

Novozymes' updated financial calendar

Novozymes and Chr. Hansen have announced that the name of the future combined company will be ‘Novonesis'. Novonesis means ‘A new beginning' and derives from the Greek word ‘genesis'. The name reflects a new era of biosolutions where innovation in biological sciences and technology will offer solutions to solve some of the biggest challenges facing humanity.

Novozymes and Chr. Hansen announce name of future combined company; Novonesis

December 12, 2023 Please see attachment. Contact information Investor Relations Disa Tuominen+45 6038 5826 dkditu@chr-hansen.com Press Relations Sanne Seyer-Hansen+45 6038 6207 dksash@chr-hansen.com Attachment 2023_Conditional competition clearance from the European Commission obtained

Update on the merger approval process for the combination of Novozymes and Chr. Hansen: Conditional competition clearance from the European Commission obtained

Danish food ingredients and enzymes makers Novozymes and Chr. Hansen are expected to secure EU antitrust approval for their all-share $22 billion tie-up based on remedies offered to address competition concerns, two people with direct knowledge of the matter said on Wednesday.

Exclusive: Novozymes, Chr. Hansen tie-up likely to win EU nod, sources say

November 20, 2023 Please see attachment. Contact information Investor Relations Anders Mohr Christensen+45 2515 2364 dkamc@chr-hansen.com Press Relations Sanne Seyer-Hansen+45 6038 6207 dksash@chr-hansen.com Attachment 2023_Update on the merger approval process for the combination of Novozymes and Chr.

Update on the merger approval process for the combination of Novozymes and Chr. Hansen: The parties have submitted a remedy proposal to the European Commission.

Novozymes has launched a new enzymatic solution that enables efficient processing of mixed feedstocks for renewable diesel and sustainable aviation fuel production.  The Danish company's Quara LowP product is designed to transform the feedstock pre-treatment process, allowing flexibility to process blends of vegetable oils with other lipid feedstocks without negatively impacting customers' bottom line.

Novozymes innovation enables blending of multiple renewable fuels

Novozymes, a global leader in biosolutions, marks a significant milestone in the renewable diesel and SAF (Sustainable Aviation Fuel) industry with the launch of Quara® LowP, an enzymatic solution designed to transform the feedstock pre-treatment process.

Novozymes launches Quara® LowP for renewable diesel feedstock pre-treatment

Investors looking for stocks in the Chemical - Specialty sector might want to consider either Axalta Coating Systems (AXTA) or Novozymes A/S (NVZMY). But which of these two companies is the best option for those looking for undervalued stocks?

AXTA vs. NVZMY: Which Stock Is the Better Value Option?

Novozymes A/S (OTCPK:NVZMF) Q3 2023 Results Conference Call October 26, 2023 3:00 AM ET Company Participants Tobias Cornelius Björklund - Head, Investor Relations Ester Baiget - Chief Executive Officer Lars Green - Chief Financial Officer Tina Fanoe - EVP, Agriculture & Industrial Biosolutions Amy Byrick - EVP, Strategy and Business Transformation Anders Lund - EVP, Consumer Biosolutions Claus Fuglsang - CSO and EVP of Research and Development. Conference Call Participants Gunther Zechmann - Bernstein Søren Samsøe - SEB Lars Topholm - Carnegie Chetan Udeshi - JPMorgan André Thormann - Danske Bank Ranulf Orr - Citi Charles Bentley - Jefferies Alex Sloane - Barclays Operator Welcome to the Novozymes conference call regarding the interim report for the first 9 months of 2023.

Novozymes A/S (NVZMF) Q3 2023 Earnings Call Transcript

After the first nine months of the 2023 financial year, Novozymes sees increasing demand for sustainable biosolutions and delivers 5 % organic sales growth. The full-year organic sales growth outlook is maintained at 4-6%.

News for Novozymes A/S Stock (NVZMY)